CS-PEI/Beclin-siRNA Downregulate Multidrug Resistance Proteins and Increase Paclitaxel Therapeutic Efficacy against NSCLC-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CS-PEI/Beclin-siRNA Downregulate Multidrug Resistance Proteins and Increase Paclitaxel Therapeutic Efficacy against NSCLC

Published:2019-09 Issue: Volume:17 Page:477-490
ISSN:2162-2531
Container-title:Molecular Therapy - Nucleic Acids
language:en
Short-container-title:Molecular Therapy - Nucleic Acids

Author:

Liu Wangta,Lo Yu-Lun,Hsu Chin,Wu Yi-Ting,Liao Zi-Xian,Wu Wen-Jeng,Chen Yi-Jou,Kao Chieh,Chiu Chien-Chih,Wang Li-Fang

Funder

Ministry of Science and Technology of Taiwan

Kaohsiung Medical University

NSYSU-KMU Joint Research Project

Publisher

Elsevier BV

Subject

Drug Discovery,Molecular Medicine

Reference49 articles.

1. Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression;Yeh;Respiration,2003

2. Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy;Kim;Nanomedicine (Lond.),2015

3. Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations;Georgiadis;Clin. Cancer Res.,1997

4. Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms;Wang;Cell Death Dis.,2016

5. Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines;Shimomura;Int. J. Oncol.,2012

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-viral vectors combined delivery of siRNA and anti-cancer drugs to reverse tumor multidrug resistance;Biomedicine & Pharmacotherapy;2024-09

2. MiR-3074-5p suppresses non-small cell lung cancer progression by targeting the YWHAZ/Hsp27 axis;International Immunopharmacology;2024-09

3. Enhancing Therapeutic Efficacy in Cancer Treatment: Integrating Nanomedicine with Autophagy Inhibition Strategies;ACS Omega;2024-06-18

4. GPRC5A promotes paclitaxel resistance and glucose content in NSCLC;Anti-Cancer Drugs;2024-04-08

5. Zebrafish tumour xenograft models: a prognostic approach to epithelial ovarian cancer;npj Precision Oncology;2024-02-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3